Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Insulin Delivery

JDRF Criticizes Medtronic/UHC For Reducing Patient Choice

Here is a brief preview of this blast: JDRF has issued a press release criticizing UnitedHealthcare's decision to extend Medtronic's exclusive status for supplying insulin pumps to its covered lives. Recall, Medtronic first signed the deal with UHC in May 2016, which applied to patients 18 years of age and older. However, with FDA's approval of the 670G pump in patients down to 7 years of age, UHC has extended the agreement to this population. Patients on existing pump therapy or patch pumps (e.g. Insulet Omnipod) are not impacted. Below, FENIX provides thoughts on UHC's decision, the potential impact to Tandem's pump business, and the potential irony of JDRF's criticism.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.